<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500849</url>
  </required_header>
  <id_info>
    <org_study_id>14017</org_study_id>
    <nct_id>NCT02500849</nct_id>
  </id_info>
  <brief_title>Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients</brief_title>
  <official_title>A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and feasibility of administering
      SB-728mR-HSPC after conditioning with busulfan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to evaluate the safety and feasibility of giving autologous
      SB-728mR-HSPC to HIV-1 (R5) infected patients who are being treated with cART and have
      undetectable virus but suboptimal CD4+ cell levels. To strengthen the possibility that
      CCR5-disrupted HSPCs engraft, patients will receive either a two- or three-day (Cohort 1 or
      Cohort 2) course of busulfan (dose targeting AUC of 4000 µM/day) before being infused with
      the genetically modified cells. At 9-12 months after SB-728mR-HSPC infusion, subjects who are
      aviremic with CD4 cell counts ≥600 cells/µL and have ≥1% CCR5-modified CD4 cells within the
      peripheral blood detected by pentamer PCR will undergo an ATI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity in subjects who received SB-728mR-HSPC after each busulfan dose level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of CD34+ HSPC collected, gene modified, and released throughout the manufacturing process</measure>
    <time_frame>Approximately first 1-2 months on study</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Detection of CCR5 modified HSPC in bone marrow</measure>
    <time_frame>Up to Month 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to hematological recovery as measured by neutrophil and platelet engraftment time</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in CD4+ T-cell percentage after SB-728mR-HSPC infusion</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in CD4+ T-cell number after SB-728mR-HSPC infusion</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in CD4/CD8 ratio after SB-728mR-HSPC infusion</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Detection of CCR5-modified PBMC in blood over time</measure>
    <time_frame>Up to Year 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HIV-1 RNA levels in plasma during the treatment interruption of antiretroviral medicines</measure>
    <time_frame>ATI Day 0 and weeks 2, 4, 6, 8, 10, 12, 14, 16 and 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Longitudinal changes of proviral DNA in PBMC</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic analysis of busulfan (AUC levels)</measure>
    <time_frame>pre-busulfan and at 15, 30, 60, 180 and 240 min after end of infusion</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cohort 1:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>target busulfan AUC levels: 8,000 µM*min (+/- 1,000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>busulfan AUC levels: 12,000 µM*min (+/- 1,000)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SB-728mR-HSPC Infusion 3 days following busulfan conditioning</intervention_name>
    <arm_group_label>Cohort 1:</arm_group_label>
    <arm_group_label>Cohort 2:</arm_group_label>
    <other_name>busulfan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maximum age 75 years for cohort 1 and 65 years for cohort 2.

          -  HIV-1 R5 seropositive with no evidence of CXCR4-tropic virus.

          -  On cART with undetectable HIV-1 (&lt;20 gc/ml HIV-1 RNA) for at least 12 months prior to
             screening evaluations.

          -  CD4+ T-cell counts ≥200 cells/µL and ≤750 cells/µL.

          -  No psychosocial conditions that would hinder study compliance and follow-up.

          -  Absence of clinically significant cardiomyopathy, congestive heart failure.

        Secondary Eligibility Criteria (for registration):

          -  Complete G-CSF/Plerixafor mobilization of HSPC.

          -  Collect ≥7.5 x 10^6 CD34+ cells/kg in two aphereses.

          -  The SB-728mR-HSPC product passed all release testing

        Exclusion Criteria:

          -  Use of AZT or maraviroc in the cART regimen.

          -  History of significant hematologic diseases such as leukemia, myelodysplasia,
             coagulopathy, and thromboembolism.

          -  Any AIDS-related opportunistic infection occurring within the past year such as
             tuberculosis, cryptococcosis and for which treatment has been unsuccessful as
             determined by the Principal Investigator.

          -  AIDS-related syndromes, infectious or otherwise, if perceived to cause excessive risk
             for morbidity post-HSPC infusion, as determined by the Principal Investigator.

          -  Patients with active HBV or HCV infection, i.e., HBV DNA and HCV RNA in blood, are
             excluded. Those with inactive, but past infection with HBV (positive HBV surface
             antigen or HBV surface antibody) or inactive HCV (positive HCV antibody), must have no
             cirrhosis, as determined by abdominal ultrasound with elastography.

          -  Active CMV retinitis or other active CMV-related organ dysfunction.

          -  CXCR4-tropic virus.

          -  Pregnant or nursing women.

          -  Any history of HIV-associated encephalopathy; dementia of any kind; seizures in the
             past 12 months; any perceived inability to directly provide informed consent.

          -  Participants may not be receiving any other investigational agents, or concurrent
             biological, chemotherapy, or radiation therapy. Participation in prior investigational
             drug or medical device study within the previous 45 days.

          -  Current or history of immunomodulatory agent or steroid use.

          -  Prior therapy with HIV vaccine or gene therapy product.

          -  History of alcohol or substance abuse for the previous 12 months.

          -  Participants with active malignancies. However, participants with skin cancers, namely
             basal cell or squamous cell carcinoma, and malignancies treated with curative intent
             having no known active disease present for ≥2 years, may be eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amrita Y. Krishnan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodica Stan, PhD</last_name>
    <phone>626-218-8330</phone>
    <email>rstan@coh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rodica Stan, PhD</last_name>
      <phone>626-218-8330</phone>
      <email>rstan@coh.org</email>
    </contact>
    <investigator>
      <last_name>Amrita Y. Krishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricella Gonzalez</last_name>
      <phone>310-557-3729</phone>
      <email>mmgonzalez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Mitsuyasu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Antunes</last_name>
      <phone>310-550-2271</phone>
      <email>Sandro.Antunes@millsclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Mills, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research, Inc.</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research, a division of eStudySite</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celia Hamilton</last_name>
      <phone>415-353-0800</phone>
      <email>chamilton@estudysite.com</email>
    </contact>
    <investigator>
      <last_name>Sandra S. Win, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Circle CARE Center, LLC</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Ulrich, RN</last_name>
      <phone>203-852-9525</phone>
      <email>gulrich@whcccc.org</email>
    </contact>
    <contact_backup>
      <last_name>Patricia R Garton, APRN</last_name>
      <phone>203-852-9525</phone>
      <email>tgarton@whcccc.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Rubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gary J. Richmond, MD, PA</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene therapy</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>HIV Infections</keyword>
  <keyword>Retroviridae Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Sexually Transmitted Diseases, Viral</keyword>
  <keyword>Sexually Transmitted Diseases</keyword>
  <keyword>Immunologic Deficiency Syndromes</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

